Edmond DE Rothschild Holding S.A. Acquires Shares of 80,000 Arvinas, Inc. (NASDAQ:ARVN)

Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 80,000 shares of the company's stock, valued at approximately $1,534,000. Edmond DE Rothschild Holding S.A. owned about 0.12% of Arvinas at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. KBC Group NV raised its holdings in shares of Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after purchasing an additional 1,255 shares during the last quarter. Quantbot Technologies LP boosted its stake in shares of Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock worth $108,000 after buying an additional 2,601 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Arvinas in the fourth quarter worth $171,000. Intech Investment Management LLC purchased a new stake in Arvinas during the third quarter valued at $350,000. Finally, Teacher Retirement System of Texas lifted its holdings in Arvinas by 19.0% in the fourth quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company's stock valued at $274,000 after acquiring an additional 2,280 shares during the period. 95.19% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Arvinas

In other Arvinas news, insider Ian Taylor sold 9,020 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. This trade represents a 5.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John G. Houston sold 31,338 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares of the company's stock, valued at $19,353,065.60. The trade was a 2.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,230 shares of company stock valued at $769,402 over the last ninety days. 5.23% of the stock is owned by company insiders.

Arvinas Trading Down 4.9 %

Shares of Arvinas stock traded down $0.34 on Friday, hitting $6.56. 3,087,482 shares of the company traded hands, compared to its average volume of 1,039,165. Arvinas, Inc. has a 52 week low of $6.24 and a 52 week high of $39.34. The company has a market cap of $451.14 million, a PE ratio of -2.37 and a beta of 2.30. The stock's 50 day moving average price is $14.15 and its 200-day moving average price is $20.04.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the previous year, the business posted ($2.53) earnings per share. As a group, research analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Wells Fargo & Company set a $26.00 price target on shares of Arvinas and gave the company an "overweight" rating in a research report on Wednesday, March 12th. HC Wainwright reiterated a "buy" rating and issued a $81.00 price target on shares of Arvinas in a research report on Tuesday, March 11th. Barclays cut their price objective on shares of Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. Oppenheimer cut Arvinas from an "outperform" rating to a "market perform" rating in a report on Tuesday, March 11th. Finally, Stifel Nicolaus reduced their price target on Arvinas from $63.00 to $51.00 and set a "buy" rating for the company in a research report on Wednesday, February 12th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Arvinas has a consensus rating of "Moderate Buy" and an average target price of $35.50.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.